Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.51 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.51 |
| ▸ | RXRA | P19793 | 2/20 | 0.51 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 8/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3416378 | 0.90 | FFAR1 (0.57) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL3413762 | 0.89 | NR1H2 (0.55) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL3419226 | 0.88 | FFAR1 (0.50) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL3418553 | 0.88 | FFAR1 (0.55) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL3415596 | 0.86 | NR1H2 (0.45) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL3416635 | 0.86 | FFAR1 (0.50) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL3415693 | 0.83 | EGLN1 (0.54) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL3417453 | 0.83 | FFAR1 (0.52) | NR1H2NR1H3RXRAEGLN1FFAR1 | |
| SCHEMBL13008821 | 0.82 | NR1H4 (0.60) | NR1H2NR1H3RXRANR1H4RXRB | |
| SCHEMBL3416922 | 0.82 | RXRA (0.55) | NR1H2NR1H3RXRAEGLN1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-7687664-B2 | Carboxylic acid derivative, a salt thereof or an ester of them, and medicament comprising it | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-10-28 | — | — | US | disclosed |
| EP-1394147-A1 | CARBOXYLIC ACID DERIVATIVE AND MEDICINE COMPRISING SALT OR ESTER OF THE SAME | Eisai Co., Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214888-A1 | Carboxylic acid derivative and medicine comprising salt or ester of the same | GPR119, NR3C1, INSR | NR1H2 17/4885NR1H3 15/4885RXRA 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.